Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03850964 · ClinicalTrials.gov registry record · Phase 2

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

A Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia, sponsored by Cure HHT.

Active
Registry status
Phase 2
Development phase
70
Enrollment target
11
Study locations

NCT03850964: Active Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia, sponsored by Cure HHT.

NCT03850964 is a Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia that is active but no longer recruiting, run by Cure HHT. The registered enrollment target is 70 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (84% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03850964, a Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia, is active but no longer recruiting, sponsored by Cure HHT.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
11
Study locations

Study Summary

During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.

Primary Outcome

\>=50% decrease in the duration of epistaxis in the 150 mg pazopanib arm versus the placebo arm (moderate and severe cohorts combined)

Conditions Studied

Anemia Hereditary Hemorrhagic Telangiectasia Epistaxis Nosebleed HHT

Interventions

  • DRUG Placebo oral capsule
  • DRUG Pazopanib

Study Locations (11)

California

  • University of California - Los Angeles - Los Angeles

Colorado

  • University of Colorado - Denver

Georgia

  • Augusta University - Augusta

Maryland

  • John Hopkins University - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University - St Louis

North Carolina

  • University of North Carolina - Chapel Hill

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-05-08
Est. Completion 2026-07
Phase Phase 2
Cure HHT

2 total trials

What the registry record for NCT03850964 still lists

NCT03850964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (84% lower).

The record links to 5 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.

NCT03850964 lists 11 locations in 11 states (California, Colorado, Georgia).

Frequently Asked Questions

What is clinical trial NCT03850964 about?

NCT03850964 is a clinical study titled "Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)". During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and...

What is the current status of trial NCT03850964?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-05-08. Estimated completion is 2026-07.

What conditions does trial NCT03850964 study?

This clinical trial studies the following conditions: Anemia, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nosebleed, HHT.

What interventions are being tested in trial NCT03850964?

The interventions under investigation include: Placebo oral capsule (DRUG), Pazopanib (DRUG).

Who is sponsoring clinical trial NCT03850964?

This trial is sponsored by Cure HHT, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03850964 being conducted?

This trial has 11 study locations across California, Colorado, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03850964's enrollment target sits among peer trials

70 50th of 72 higher than 22 of 72 other Anemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03850964, the US trial registry maintained by the National Library of Medicine. NCT03850964 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.